Skip to content
Clinical Trials – home
Gercor
Sponsor

Gercor

France 151 Rue Du Faubourg Saint Antoine, 75011 Paris, France

About the sponsor

Research activity centers on metastatic colorectal cancer, colorectal adenocarcinoma, and localized colon cancer, with particular interest in dMMR and MSI-H populations.

  • Immune checkpoint inhibition
  • Neoadjuvant immunotherapy
  • Watch-and-wait strategies
  • Anti-PD1-resistant disease

Clinical questions also include disease control in localized and metastatic settings, with attention to organ preservation and response assessment.

About Specializations

Gercor runs clinical trials in conditions such as Neuroendocrine tumour, Colorectal adenocarcinoma, Adenocarcinoma pancreas, Colorectal cancer metastatic, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

9 clinical trials

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gercor

Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Gercor

Study on the Effectiveness of Etoposide, Carboplatin, and Cisplatin in Patients with Localized Digestive Neuroendocrine Carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gercor

Study on the Safety and Effectiveness of Nivolumab and Ipilimumab for Patients with Metastatic Colorectal Cancer with dMMR or MSI

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Gercor

Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Gercor

Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:EXL01
  • Sponsor:Gercor

Study on Dostarlimab Immunotherapy for Patients with Localized Gastric Cancer with Deficient Mismatch Repair or High Microsatellite Instability

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Gercor

Colon cancer

Not yet recruiting

Study on Pembrolizumab and Drug Combination for Patients with Localized Colon Cancer with Specific Genetic Markers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gercor

Neuroendocrine tumour

Not yet recruiting

Study on the Effectiveness of Etoposide, Carboplatin, and Cisplatin in Patients with Localized Digestive Neuroendocrine Carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gercor

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.